ESPREsperion Therapeutics Inc.
ESPR
Esperion Therapeutics Inc.9,311
Mkt Cap
$889.5MVolume
7.39M52W High
$3.9452W Low
$0.6925PE Ratio
-6.89ESPR Fundamentals
Price
$3.99Prev Close
$3.69Open
$3.7050D MA
$2.81Beta
1.05Avg. Volume
7.54MEPS (Annual)
-$0.2764P/B
-1.68Rev/Employee
$1.09MTraders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...
MarketBeat·3h ago
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler
Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...
MarketBeat·6h ago
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 4.1% - Should You Buy?
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 4.1% - Still a Buy...
MarketBeat·5d ago
Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol
(RTTNews) - Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing...
Nasdaq News: Markets·8d ago
HC Wainwright Has Positive Outlook for ESPR FY2025 Earnings
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday...
MarketBeat·17d ago
Research Analysts Set Expectations for ESPR FY2026 Earnings
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to...
MarketBeat·18d ago
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss...
MarketBeat·19d ago
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Zacks·19d ago
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago